DC67602 · Updated 27 October 2026
ILB-3132
Instructions for Use
Before use
Check the supplied lot number, batch COA, approved SDS, quantity and retest date. Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
For small quantities of viscous or oily lipid, volumetric transfer can reduce weighing losses. Confirm solvent compatibility and solubility before preparing a stock; calculated volumes do not establish solubility.
Stock-solution planning
Volume (mL) = mass (mg) × 1000 / [molecular weight × concentration (mM)].
| Mass | 10 mM | 20 mM |
|---|---|---|
| 10 mg | 1.1516 mL | 0.5758 mL |
| 25 mg | 2.8791 mL | 1.4395 mL |
| 50 mg | 5.7581 mL | 2.8791 mL |
| 100 mg | 11.5163 mL | 5.7581 mL |
Literature formulation reference
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| E12LA6B6O3 (catalog structure) | DC67602 | 868.335 | Not assigned | Not calculable from disclosed data |
| DSPC | DC57005 | 790.15 | Not assigned | Not calculable from disclosed data |
| Cholesterol | DCD-041 | 386.65 | Not assigned | Not calculable from disclosed data |
| DMG-PEG2000 | DC40169 | 2507 | Not assigned | Not calculable from disclosed data |
The patent uses the named four-component system for reporter and OVA-mRNA experiments. The separate Example 40 series contains an unresolved discrepancy between the narrative and Table 4. The affected formulations must not be represented as a single verified recipe or used as a default calculator input.
Read the complete study conditions, biological results, tolerability and figures →
References
- Fang W, Qin H, Xu Y, Wu Q. Amino lipid, and lipid nanoparticles and use thereof. WO2024198497A1, published October 3, 2024. Example 2; Examples 36–40; Tables 1–5; Figures 2–3.
- WO2024198497A9, corrected publication September 18, 2025. Corrected searchable text reviewed; figure and table identity not fully reverified.
- MagicRNA. ASGCT 28th Annual Meeting announcement, April 30, 2025. Sponsor-level naming of ILB-3132; not a disclosed molecular structure.
- Wang Q, et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. 2025;393:1542–1544. DOI: 10.1056/NEJMc2509522. Background platform reference only.